Quick Answer
AGIOS PHARMACEUTICALS, INC. reported Research And Development Expense of $339.54 million for the year ending 2025.
- AGIOS PHARMACEUTICALS, INC. showed an increase of +12.7% in Research And Development Expense from 2024 to 2025.
- This data is from AGIOS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2011 to 2025), AGIOS PHARMACEUTICALS, INC.'s Research And Development Expense has grown by 986.4%.
- Historical annual values: Fiscal year 2025: $339.54 million | Fiscal year 2024: $301.29 million | Fiscal year 2023: $295.53 million | Fiscal year 2022: $279.91 million | Fiscal year 2021: $256.97 million | Fiscal year 2020: $220.81 million | Fiscal year 2019: $214.26 million | Fiscal year 2018: $341.32 million | Fiscal year 2017: $292.68 million | Fiscal year 2016: $220.16 million | Fiscal year 2015: $141.83 million | Fiscal year 2014: $100.37 million | Fiscal year 2013: $54.50 million | Fiscal year 2012: $41.04 million | Fiscal year 2011: $31.25 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: